Israeli company Brainsway Ltd. has received CE Mark for its Deep TMS system to treat neuropathic chronic pain (“neuropathic pain”). This indication adds to the treatments already CE marked, which include clinical depression among others.
Brainsway is dedicated to the development and marketing of Deep TMS (Transcranial Magnetic Stimulation) systems – novel, noninvasive medical devices for treatment of a wide range of neurological and psychopathological disorders.
According to Brainsway’s website TMS is a noninvasive technique used to apply brief magnetic pulses to the brain. The pulses are administered by passing high currents through an electromagnetic coil placed adjacent to a patient’s scalp. The pulses induce an electric field in the underlying brain tissue. When the induced field is above a certain threshold, and is directed in an appropriate orientation relative the brain’s neuronal pathways, localised axonal depolarisations are produced, thus activating the neurons in the relevant brain structure.
In principle, any brain-related disorder that is associated with pathological activity of specific brain sites may be treated by this method. Potential applications include addiction, schizophrenia, obesity, eating disorders, Parkinson’s disease, Alzheimer’s disease, autism and post-traumatic stress disorder.
“Neuropathic pain is the sixth indication for which Deep TMS has achieved CE Mark approval,” commented Uzi Sofer, Brainsway’s CEO. “Previous CE Marks were for clinical depression, bi-polar disorder, schizophrenia (negative symptoms), Parkinson’s diseases and post-traumatic stress disorder. As our therapeutic pipeline continues to expand, it is very exciting to continue to bring proven new Deep TMS treatments to market.”
Source: Brainsway Ltd., Globe Newswire